RUA Life Sciences Interim Results: Profitable Transformation and Strategic Value Creation

RUA Life Sciences interim results show a real trading turnaround

RUA Life Sciences has put out a genuinely better set of interim numbers for the six months to 31 March 2026. This is not a story of explosive growth, but it is a story of a business getting more disciplined, less lossmaking and much closer to sustainable profitability.

The headline message is simple: revenue rose, margins stayed strong, costs fell and adjusted EBITDA moved into profit. That matters because RUA has spent the last couple of years trying to shift from an R&D-heavy medical devices business into a more commercial contract manufacturing and biomaterials group. These results suggest that shift is starting to work.

Key metric	H1 2026	H1 2025	What changed
Revenue	£2.747 million	£2.589 million	Up 6.1%
Gross profit	£2.058 million	£1.903 million	Up 8.1%
Gross margin	74.9%	73.5%	Improved
Operating loss	£234k	£685k	Loss reduced by 66%
Adjusted EBITDA	£76k profit	£227k loss	Improved by £303k
Loss before tax	£183k	£641k	Much improved
Loss after tax	£203k	£635k	Much improved
Cash	£2.365 million	£3.567 million	Lower year on year

One thing worth flagging straight away: the highlights section says “post tax loss £183k”, but the financial statements show a loss before tax of £183k and a loss after tax of £203k. Retail investors should always check the detail, and in this case the detail matters.

RUA revenue growth came from biomaterials, while medical devices had mixed underlying trends

Revenue increased to £2.747 million, but the mix tells the more interesting story. The Medical Devices and Components division brought in £2.253 million, only slightly ahead of £2.240 million a year earlier. So the group did grow, but not because every part of the business was firing.

The bigger boost came from Biomaterials, where revenue rose from £349k to £490k. RUA says this included historical underpayments identified after an audit of royalties from licensees. That is positive because it brings cash and confirms value in the IP, but investors should be careful not to assume every pound of that uplift is recurring.

Within Medical Devices and Components, the UK business grew revenue by 32% thanks to new development contracts. Development contracts are projects where RUA helps design or develop products for customers, rather than simply manufacturing them. That is encouraging because it can feed future production work.

However, Abiss France had a weaker half. Its major customer is holding excess inventory and going through a rationalisation period, which hit revenue. In plain English, the customer has too much stock and is buying less for now. That is a short-term drag and a reminder that customer concentration risk is real.

RUA margin improvement and cost control are the best parts of this update

The strongest feature in these interim results is operational discipline. Gross margin improved to 74.9% from 73.5%, while administrative expenses fell 6.2% to £2.314 million despite inflationary pressures.

That combination is exactly what you want to see in a small medtech business trying to prove it can scale sensibly. RUA is not just buying growth. It is holding the line on costs and turning more of its revenue into gross profit.

There was a slight margin dip compared with the 78.5% achieved in the eighteen months to 30 September 2025, but management explains that clearly. Lower activity at Abiss France and a higher share of lower-margin UK development contracts weighed on profitability, partly offset by the higher contribution from Biomaterials, which carries near 100% margin.

Adjusted EBITDA came in at a £76k profit versus a £227k loss last time. Adjusted EBITDA is a measure of underlying trading performance that strips out items like depreciation, amortisation and share-based payments. It is not the same as cash profit, but here it does show that the core trading business is moving in the right direction.

RUA cash fell sharply, so this is not a risk-free recovery story

Now for the less cheerful bit. Cash fell to £2.365 million from £3.250 million at 30 September 2025 and from £3.567 million a year earlier. Net cash outflow from operating activities was £758k.

The main reason was working capital. That means more cash got tied up in receivables and inventories. Trade and other receivables rose to £1.769 million from £1.250 million at the September year-end, while inventories increased to £960k from £894k.

Management says this is typical for the six months to March and expects the cash position to improve by year-end as those effects reverse. That may happen, but for now investors should be honest about it: profits are improving faster than cash conversion. Until cash starts behaving better, the market is unlikely to give full credit for the turnaround.

RUA Structural Heart spin-out could be the hidden value driver

The biggest strategic development happened after the period end, and it could end up being the most important part of the whole announcement. RUA Structural Heart, or RSH, completed a spin-out and third-party funding round in May 2026.

Why does that matter? First, it validates outside investor interest in AurTex, RUA’s structural heart valve material platform. Second, RSH will no longer be consolidated into group results because RUA has lost control for accounting purposes. That means the losses from this development-stage business should no longer weigh directly on the group income statement in the same way.

RUA says the funding deal set a £10 million valuation floor for the next financing round. That is useful as a reference point, but it is not the same thing as cash in the bank for RUA shareholders today. The company also mentions that comparable heart valve technologies have reached £40 million pre-money valuations at the end of pre-clinical development and over £1 billion exit values in TAVR platform deals. Interesting, yes. Guaranteed, absolutely not.

Still, this is probably the most exciting part of the story. If the core manufacturing business can get profitable while the group also holds stakes in potentially valuable spin-outs, that gives RUA a more interesting investment case than a plain contract manufacturer.

Abiss strategy shift adds upside, but execution risk is obvious

RUA is also rethinking Abiss. The plan is to shift it over two years from a contract manufacturing operation into a Europe-focused urogynaecology specialist selling pelvic floor products.

That sounds sensible on paper because the company says the product portfolio has not been actively exploited due to concerns about conflict with its major customer. If that conflict can be managed, there may be real value there. RUA even hints that it could use the same outside investor model for Abiss as it did for RSH.

But this is still a plan, not a delivered outcome. Investors should treat it as upside potential rather than bankable value today.

What this RUA Life Sciences RNS means for retail investors

My take is broadly positive. The underlying business is improving in a credible way, and that is backed up by better margins, lower costs and a swing to positive adjusted EBITDA. The chairman’s claim that the group could become profitable in the second half of the current year now looks plausible rather than promotional.

The caution points are also clear. Cash has fallen, some Biomaterials growth came from royalty catch-up, and Abiss France is under pressure because of customer inventory issues. This is better, but it is not yet bulletproof.

For retail investors, the key question is whether RUA can now do two things at once: make the core business properly profitable and unlock value from its IP-led assets. If it can, this could become a much stronger story. If not, the market may keep viewing it as a small, complicated medtech with too many moving parts.

Right now, the results suggest management is earning the benefit of the doubt. Not a victory lap yet, but definitely a step in the right direction.